Kadimastem

38 articles with Kadimastem

• Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory

  9/28/2022

  Kadimastem Ltd. has been granted its third patent approval for the company's innovative cell selection and enrichment technology and its use in the production of IsletRx, the company's treatment and potential cure for diabetes. 

• ILEX Medical to Invest 10 million NIS ($3.2 million) in Kadimastem

  11/29/2021

  Kadimastem Ltd. announces a raise of 10 million NIS ($3.2 million) from ILEX Medical (TASE: ILX) one of the largest healthcare companies in Israel, in a private financing round.

• 

  Global Roundup: Mallinckrodt Shares Real-World Data for Terlipressin

  10/28/2021

  Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
• 

  Global Roundup: Singapore's AUM Biosciences Earns $27 Million in Series A Round

  10/14/2021

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
• 

  Global Roundup: UK Expands Life Sciences Ecosystem with Formation of We Are Pioneering Group

  4/29/2021

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS

  3/9/2021

  Kadimastem Ltd., a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis.

• Kadimastem Announces Executive Management Changes

  2/1/2021

  Company Appoints Biotech Industry Leaders Ronen Twito, CPA as Co-Chairperson and Doron Birger and Ron Mayron to the Company's Board of Directors

• 

  Clinical Catch-Up: December 14-18

  12/21/2020

  Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
• 

  Clinical Catch-Up: August 10-14

  8/17/2020

  It was a very busy week for clinical trial updates. Here’s a look.
• 

  Clinical Catch-Up: August 3-7

  8/10/2020

  It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

• Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS

  8/3/2020

  Kadimastem Ltd., announced that its lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company's Phase 1/2a clinical trial in ALS.

• Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

  1/6/2020

  Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, today announced promising results of cohort A of its Phase 1/2a clinical trial for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).

• Kadimastem Announces Successful Preclinical Results of Its Cell Therapy Treatment for Insulin-dependent Diabetes

  11/19/2019

  Study results demonstrate IsletRx cells ability to balance blood sugar levels and maintain normal levels over time

• Kadimastem Intends to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol Following Recent Positive Interim Results

  11/18/2019

  The Company intends to assess the safety and efficacy of a repeated administration of the low dose of AstroRx® cells in Cohort C

• Kadimastem Announces Promising Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS

  9/24/2019

   Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, today announced promising interim results of cohort A of its Phase 1/2a clinical trial for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).

• Kadimastem Announces Leadership Changes

  5/29/2019

  Kadimastem, a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef has stepped down as Chief Executive Officer.

• Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A in Phase I/IIa of Its Clinical Trial

  2/27/2019

  Israeli biotechnology company Kadimastem announced the completion of cell transplantation in 5 patients who were enrolled in Cohort A for its clinical trial in ALS.

• Kadimastem and Defymed Awarded Grant in the EU's Prestigious Eurostars Program for the Clinical Development of an Integrated Product for the Treatment of Diabetes

  11/12/2018

  The projected project budget is NIS 5.4 million for two years, with Kadimastem's share for the first year being NIS 1.5 million. The participation of the Innovation Authority will be at the rate of 50% of the Kadimastem budget

• Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem

  10/9/2018

  For the first time ever, the company has transplanted cells derived from embryonic stem cells in ALS patients

• Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem

  10/2/2018

  Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of an investment round of $5.15 million, by way of private placement, at a share price of 65 agorot.